Opinion
Video
Overview of Non-Muscle Invasive Bladder Cancer (NMIBC)
Experts in urology discuss the importance of evaluation to accurately identify the stage and grade of NMIBC, which plays a crucial role in determining the risk category focusing on the distinction between low and high-grade tumors and the significance for each patient with NMIBC.
This is a synopsis of the Viewpoints video series featuring moderator, Sam S. Chang, MD, MBA, from Vanderbilt University School of Medicine, and panelists Gary Steinberg, MD, FACS, from Rush University Medical Center, Mark Tyson, MD, of Mayo Clinic Phoenix, Roger Li, MD, from Moffitt Cancer Center, and Sandip M. Prasad, MD, MPhil, of Morristown Medical Center.
In the inaugural episode of Urology Times® Viewpoints, Dr. Sam Chang, a urologist at Vanderbilt University in Nashville, Tennessee, leads a panel of distinguished experts in discussing the latest in NMIBC. The panel includes Dr. Gary Steinberg from Rush University in Chicago, Dr. Sandip Prasad from Morristown Medical Center in New Jersey, Dr. Mark Tyson, a urologic oncologist at Mayo Clinic in Scottsdale, Arizona, and Dr. Roger Lee, a urologic oncologist at the Moffitt Cancer Center in Tampa, Florida.
The focus of the discussion is on accurately identifying the stage and grade of NMIBC, crucial for determining the appropriate risk category for each patient. The panel emphasizes the distinction between low-grade tumors, which are generally favorable and relatively indolent in terms of their progression, and high-grade tumors, which carry the potential for invasiveness and even metastasis. Staging in NMIBC is classified as either stage TA, indicating superficial disease, or T1, suggesting invasive disease. These classifications help define low, intermediate, and high-risk diseases. Furthermore, the panelists delve into the nuances of upper versus lower tract diseases. They highlight the more aggressive nature and higher risk associated with upper tract disease, underscoring the importance of early detection and accurate staging. They also discuss the genetic similarities and differences between upper and lower tract diseases and how these factors influence therapeutic interventions and future treatment strategies.
The episode serves as a comprehensive guide for healthcare professionals in understanding the complexities of NMIBC, from staging and grading to the implications of tumor location and the significance of genetic factors in treatment planning.
*Video synopsis is AI-generated and reviewed by Urology Times® editorial staff.
